Human Vaccines Market - by Product Type (Influenza, Pneumococcal, HPV, Hepatitis, Rotavirus, Meningococcal, Mumps, Measles, Typhoid, and Others), by Vaccine Type (Attenuated, Recombinant, Conjugate, Combination, Inactivated, and Others), by Age Group (Adolescent, Pediatrics, Geriatrics, and Adult), by Distribution Channel (Drugstores, Hospital, Pharmacies, and Others), and by Region: Global Industry Perspective, Comprehensive Analysis, and Forecast 2020 – 2026

Published Date: 25-Aug-2020 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-2806 Status : Published

Global Human Vaccines Market was valued at USD 41.70 Billion in 2019 and is expected to reach over USD 69.8 Billion by 2026, growing at a CAGR of around 7.5% during the forecast period from 2020 to 2026

Description

According to the report, the global Human Vaccines Market was valued at USD 41.70 Billion in 2019 and is expected to reach over USD 69.8 Billion by 2026, growing at a CAGR of around 7.5% during the forecast period from 2020 to 2026.

The demand for Human Vaccines Market is increasing significantly due to high prevalence of infectious diseases in majorly developing and least developed countries, and increased spending by government agencies on healthcare. Furthermore, advancements in research and development has led to the growth of personalized medicine which will further boost the demand for human vaccines worldwide.

Global Human Vaccines Market: Overview

Vaccination is always been promoted as a very important public health intercession across the world for decades. According to the (WHO) World Health Organization, vaccination has decreased the worldwide burden of contagious disease/syndrome to a great extent. An exceptionally low risk of severe and deadly side effects related to vaccines and increasing understanding related to vaccination by different government and non-profit associations are the most important factors fuelling the global human vaccines market.

Global Human Vaccines Market: Growth Factors

The global human vaccines market is expected to witness tremendous expansion rate, due to the growing awareness about the benefits of vaccines as compared to other modes of medicine/drug administrations. As vaccines show a considerably less risk of severe side-effects as compared to other anticipated products there is an increasing popularity of the human vaccines market. On the other hand, the growing number of awareness/knowledge programs by different governments and non-profit organizations as well as private associations also anticipates supporting the development and expansion of this market in the coming future.

Human Vaccines Market

The global market for human vaccines is projected to increase and develop at a rapid rate in the future. However, the existence of strict regulatory rules is expected to create obstacles to the growth of this market. Besides, the rapid increase in the cost of these vaccines, along with the handling, transportation, and storage, is also likely to act as a major restraint for the global market in the coming years.

Global Human Vaccines Market: Segmentation

The global human vaccines market has been classified based on products, vaccine type, distribution channel, age group, and geography. In terms of vaccine type, the market is categorized into attenuated, recombinant, conjugate, combination, inactivated, and others. Similarly, based on the product, the human vaccines market is divided into influenza, pneumococcal, HPV, hepatitis, rotavirus, meningococcal, mumps, measles, typhoid, and others. Based on age group, the market is classified into adolescent, pediatrics, geriatrics, and adult. Based on distribution channel, the human vaccines market is categorized into drugstores, hospital, pharmacies, and others.

Global Human Vaccines Market: Regional Analysis

Geographically, the human vaccines market is classified into Europe, North America, the Middle East and Africa, and Asia-Pacific. North America is anticipated to hold the leading position, due to the accessibility of improved healthcare facilities in the region. North America is followed by Europe.

The Middle East & Africa offer huge opportunities and potential for the global human vaccines market. Other factors that are fuelling the market growth in other regions are the policies of international bodies, for instance, World health organization (WHO), growing funds from philanthropy associations such as Melinda Gates and Bill foundation, manufacturing of new vaccines, increasing knowledge of vaccination, development of manufacturing low price vaccines particularly in developing countries. The entrance of China in the human vaccines market affects positively the Asia Pacific region.

Global Human Vaccines Market: Competitive Players

Some of the most important market players in the human vaccines market are GeneOne Life Science Inc., Inovio Pharmaceuticals, Inc., Immunomic Therapeutics, Inc., MedImmune, Pharos Biologicals, Astellas Pharma, Inc., Hoffmann-La Roche AG, Sanofi S.A., F. Boehringer Ingelheim GmbH., and CureVac, among others.

Global Human Vaccines Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • The UK
    • France
    • Germany
  • The Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

What Reports Provides

  • Full in-depth analysis of the parent market
  • Important changes in market dynamics
  • Segmentation details of the market
  • Former, on-going, and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of major players
  • Emerging segments and regional markets
  • Testimonials to companies in order to fortify their foothold in the market.

Table Of Content

  • Chapter 1 Preface
    • 1.1 Report Description
    • 1.1 Report Scope
  • Chapter 2 Research Methodology
    • 2.1 Research Methodology
    • 2.2 Secondary Research
    • 2.3 Primary Research
    • 2.4 Models
      • 2.4.1 Company Share Analysis Model
      • 2.4.2 Revenue Based Modeling
    • 2.5 Research Limitations
  • Chapter 3 Executive Summary
    • 3.1 Global Human Vaccines Market, 2016 – 2026 (USD Billion)
    • 3.2 Global Human Vaccines Market: Snapshot
  • Chapter 4 Human Vaccines Market – Industry Analysis
    • 4.1 Introduction
    • 4.2 Market Drivers
      • 4.2.1 Driving Factor 1 Analysis
      • 4.2.2 Driving Factor 2 Analysis:
    • 4.3 Market Restraints
      • 4.3.1 Restraining Factor Analysis
    • 4.4 Market Opportunities
      • 4.4.1 Market Opportunity & Use-case Analysis
      • 4.4.2 Use – Cases for Human Vaccines
    • 4.5 Porter’s Five Forces Analysis
    • 4.6 COVID 19 Impact Analysis
      • 4.6.1.1 Impact on Product Development and Technology Adoption
      • 4.6.1.2 Gap Analysis
  • Chapter 5 Investment Proposition Analysis
    • 5.1 Global Human Vaccines Market Attractiveness, By Products
    • 5.2 Global Human Vaccines Market Attractiveness, By Age Group
    • 5.3 Global Human Vaccines Market Attractiveness, By Distribution Channel
    • 5.4 Global Human Vaccines Market Attractiveness, By Type
    • 5.5 Global Human Vaccines Market Attractiveness, By Region
  • Chapter 6 Competitive Landscape
    • 6.1 Company Market Share Analysis - 2019
      • 6.1.1 Global Human Vaccines Market: Company Market Share, 2019
    • 6.2 Strategic Developments
    • 7.1 Global Human Vaccines Market Overview: by Products
      • 7.1.1 Global Human Vaccines Market Revenue Share, by Products, 2019 & 2026
    • 7.2 Global Human Vaccines Market Analysis/Overview – By Products
      • 7.2.1 Influenza – Overview/Analysis
      • 7.2.2 Pneumococcal – Overview/Analysis
      • 7.2.3 HPV – Overview/Analysis
      • 7.2.4 Hepatitis – Overview/Analysis
      • 7.2.5 Rotavirus – Overview/Analysis
      • 7.2.6 Meningococcal – Overview/Analysis
      • 7.2.7 Mumps – Overview/Analysis
      • 7.2.8 Measles – Overview/Analysis
      • 7.2.9 Typhoid – Overview/Analysis
      • 7.2.10 Others – Overview/Analysis
    • 7.3 Influenza
      • 7.3.1 Global Human Vaccines Market for Influenza, Revenue (USD Billion) 2016 - 2026
    • 7.4 Pneumococcal
      • 7.4.1 Global Human Vaccines Market for Pneumococcal, Revenue (USD Billion) 2016 - 2026
    • 7.5 HPV
      • 7.5.1 Global Human Vaccines Market for HPV, Revenue (USD Billion) 2016 - 2026
    • 7.6 Hepatitis
      • 7.6.1 Global Human Vaccines Market for Hepatitis, Revenue (USD Billion) 2016 - 2026
    • 7.7 Rotavirus
      • 7.7.1 Global Human Vaccines Market for Rotavirus, Revenue (USD Billion) 2016 - 2026
    • 7.8 Meningococcal
      • 7.8.1 Global Human Vaccines Market for Meningococcal, Revenue (USD Billion) 2016 - 2026
    • 7.9 Mumps
      • 7.9.1 Global Human Vaccines Market for Mumps, Revenue (USD Billion) 2016 - 2026
    • 7.10 Measles
      • 7.10.1 Global Human Vaccines Market for Measles, Revenue (USD Billion) 2016 - 2026
    • 7.11 Typhoid
      • 7.11.1 Global Human Vaccines Market for Typhoid, Revenue (USD Billion) 2016 - 2026
    • 7.12 Others
      • 7.12.1 Global Human Vaccines Market for Others, Revenue (USD Billion) 2016 - 2026
    • 8.1 Global Human Vaccines Market Overview: by Age Group
      • 8.1.1 Global Human Vaccines Market Revenue Share, by Age Group, 2019 & 2026
    • 8.2 Global Human Vaccines Market Analysis/Overview – By Age Group
      • 8.2.1 Adulescent – Overview/Analysis
      • 8.2.2 Pediatrics – Overview/Analysis
      • 8.2.3 Geriatrics – Overview/Analysis
      • 8.2.4 Adult – Overview/Analysis
    • 8.3 Adulescent
      • 8.3.1 Global Human Vaccines Market for Adulescent, Revenue (USD Billion) 2016 - 2026
    • 8.4 Pediatrics
      • 8.4.1 Global Human Vaccines Market for Pediatrics, Revenue (USD Billion) 2016 - 2026
    • 8.5 Geriatrics
      • 8.5.1 Global Human Vaccines Market for Geriatrics, Revenue (USD Billion) 2016 - 2026
    • 8.6 Adult
      • 8.6.1 Global Human Vaccines Market for Adult, Revenue (USD Billion) 2016 - 2026
    • 9.1 Global Human Vaccines Market Overview: by Distribution Channel
      • 9.1.1 Global Human Vaccines Market Revenue Share, by Distribution Channel, 2019 & 2026
    • 9.2 Global Human Vaccines Market Analysis/Overview – By Distribution Channel
      • 9.2.1 Drugstores – Overview/Analysis
      • 9.2.2 Hospital – Overview/Analysis
      • 9.2.3 Pharmacies – Overview/Analysis
      • 9.2.4 Others – Overview/Analysis
    • 9.3 Drugstores
      • 9.3.1 Global Human Vaccines Market for Drugstores, Revenue (USD Billion) 2016 - 2026
    • 9.4 Hospital
      • 9.4.1 Global Human Vaccines Market for Hospital, Revenue (USD Billion) 2016 - 2026
    • 9.5 Pharmacies
      • 9.5.1 Global Human Vaccines Market for Pharmacies, Revenue (USD Billion) 2016 - 2026
    • 9.6 Others
      • 9.6.1 Global Human Vaccines Market for Others, Revenue (USD Billion) 2016 - 2026
    • 10.1 Global Human Vaccines Market Overview: by Type
      • 10.1.1 Global Human Vaccines Market Revenue Share, by Type, 2019 & 2026
    • 10.2 Global Human Vaccines Market Analysis/Overview – By Type
      • 10.2.1 Attenuated – Overview/Analysis
      • 10.2.2 Recombinant – Overview/Analysis
      • 10.2.3 Conjugate – Overview/Analysis
      • 10.2.4 Combination – Overview/Analysis
      • 10.2.5 Inactivated – Overview/Analysis
      • 10.2.6 Others – Overview/Analysis
      • 10.2.7 Others – Overview/Analysis
    • 10.3 Attenuated
      • 10.3.1 Global Human Vaccines Market for Attenuated, Revenue (USD Billion) 2016 - 2026
    • 10.4 Recombinant
      • 10.4.1 Global Human Vaccines Market for Recombinant, Revenue (USD Billion) 2016 - 2026
    • 10.5 Conjugate
      • 10.5.1 Global Human Vaccines Market for Conjugate, Revenue (USD Billion) 2016 - 2026
    • 10.6 Combination
      • 10.6.1 Global Human Vaccines Market for Combination, Revenue (USD Billion) 2016 - 2026
    • 10.7 Inactivated
      • 10.7.1 Global Human Vaccines Market for Inactivated, Revenue (USD Billion) 2016 - 2026
    • 10.8 Others
      • 10.8.1 Global Human Vaccines Market for Others, Revenue (USD Billion) 2016 - 2026
    • 10.9 Others
      • 10.9.1 Global Human Vaccines Market for Others, Revenue (USD Billion) 2016 - 2026
  • Chapter 11 Human Vaccines Market – Regional Analysis
    • 11.1 Global Human Vaccines Market: Regional Overview
      • 11.1.1 Global Human Vaccines Market Revenue Share, by Region, 2019 & 2026
      • 11.1.2 Global Human Vaccines Market Revenue, by Region, 2016 – 2026 (USD Billion)
    • 11.2 North America
      • 11.2.1 North America Human Vaccines Market Revenue, 2016 - 2026 (USD Billion)
      • 11.2.2 North America Human Vaccines Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 11.2.3 North America Human Vaccines Market Revenue, by Products, 2016 – 2026
      • 11.2.4 North America Human Vaccines Market Revenue, by Age Group, 2016 – 2026
      • 11.2.5 North America Human Vaccines Market Revenue, by Distribution Channel, 2016 – 2026
      • 11.2.6 North America Human Vaccines Market Revenue, by Type, 2016 – 2026
      • 11.2.7 U.S.
      • 11.2.8 Canada
    • 11.3 Europe
      • 11.3.1 Europe Human Vaccines Market Revenue, 2016 - 2026 (USD Billion)
      • 11.3.2 Europe Human Vaccines Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 11.3.3 Europe Human Vaccines Market Revenue, by Products, 2016 – 2026
      • 11.3.4 Europe Human Vaccines Market Revenue, by Age Group, 2016 – 2026
      • 11.3.5 Europe Human Vaccines Market Revenue, by Distribution Channel, 2016 – 2026
      • 11.3.6 Europe Human Vaccines Market Revenue, by Type, 2016 – 2026
      • 11.3.7 Germany
      • 11.3.8 France
      • 11.3.9 U.K.
      • 11.3.10 Rest of Europe
    • 11.4 Asia Pacific
      • 11.4.1 Asia Pacific Human Vaccines Market Revenue, 2016 - 2026 (USD Billion)
      • 11.4.2 Asia Pacific Human Vaccines Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 11.4.3 Asia Pacific Human Vaccines Market Revenue, by Products, 2016 – 2026
      • 11.4.4 Asia Pacific Human Vaccines Market Revenue, by Age Group, 2016 – 2026
      • 11.4.5 Asia Pacific Human Vaccines Market Revenue, by Distribution Channel, 2016 – 2026
      • 11.4.6 Asia Pacific Human Vaccines Market Revenue, by Type, 2016 – 2026
      • 11.4.7 China
      • 11.4.8 India
      • 11.4.9 Rest of Asia Pacific
    • 11.5 Latin America
      • 11.5.1 Latin America Human Vaccines Market Revenue, 2016 - 2026 (USD Billion)
      • 11.5.2 Latin America Human Vaccines Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 11.5.3 Latin America Human Vaccines Market Revenue, by Products, 2016 – 2026
      • 11.5.4 Latin America Human Vaccines Market Revenue, by Age Group, 2016 – 2026
      • 11.5.5 Latin America Human Vaccines Market Revenue, by Distribution Channel, 2016 – 2026
      • 11.5.6 Latin America Human Vaccines Market Revenue, by Type, 2016 – 2026
      • 11.5.7 Brazil
      • 11.5.8 Rest of Latin America
    • 11.6 The Middle-East and Africa
      • 11.6.1 The Middle-East and Africa Human Vaccines Market Revenue, 2016 - 2026 (USD Billion)
      • 11.6.2 The Middle-East and Africa Human Vaccines Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 11.6.3 The Middle-East and Africa Human Vaccines Market Revenue, by Products, 2016 – 2026
      • 11.6.4 The Middle-East and Africa Human Vaccines Market Revenue, by Age Group, 2016 – 2026
      • 11.6.5 The Middle-East and Africa Human Vaccines Market Revenue, by Distribution Channel, 2016 – 2026
      • 11.6.6 The Middle-East and Africa Human Vaccines Market Revenue, by Type, 2016 – 2026
      • 11.6.7 GCC Countries
      • 11.6.8 Rest of Middle-East Africa
  • Chapter 12 Company Profiles
    • 12.1 GeneOne Life Science Inc.
      • 12.1.1 Company Overview
      • 12.1.2 Financial Overview
      • 12.1.3 Product Portfolio
      • 12.1.4 Business Strategy
      • 12.1.5 Recent Developments
    • 12.2 Inovio Pharmaceuticals, Inc.
    • 12.3 Immunomic Therapeutics
    • 12.4 MedImmune
    • 12.5 Pharos Biulogicals
    • 12.6 Astellas Pharma, Inc.
    • 12.7 Hoffmann-La Roche AG
    • 12.8 Sanofi S.A
      • 12.9 F. Boehringer Ingelheim GmbH

Methodology

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com